Two Novel Product Platforms

FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms:

  • Anti-angiogenic/Anti-tubulin (AA/AT) Compounds:  Investigational water-soluble small molecule drugs designed to harness the power of two well-understood anti-cancer activities into one molecular function.
    • Brain Cancer (GBM)
    • Triple Negative Breast Cancer (TNBC)
       
  • Folate-targeted Anti-cancer (FTAC) Compounds:  Investigational water-soluble small molecule drugs designed to specifically target and destroy tumor cells.
    • Mesothelioma
    • Pancreatic Cancer

Latest News

FLAG Therapeutics awarded $1,500,000 Phase II SBIR - Development of Novel Targeted Chemotherapeutics for the Treatment of Malignant Pleural Mesothelioma

FLAG Therapeutics awarded 8 additional patents in 2017

Upcoming Presentations

ABTC (Adult Brain Tumor Consortium) Annual Meeting - January 11, 2018, Baltimore MD

MABA (MidAtlantic BioAngels) Meeting - January 16, 2018, New York City